Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
24/03/2026 11:11
March 24 (Reuters) - Karyopharm Therapeutics KPTI.O said on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a late‑stage trial in patients with a rare blood cancer, one of the study's main goals. However, the drug missed the other goal of showing an improvement in patients' symptoms. (Reporting by Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri) ((Puyaan.Singh@thomsonreuters.com;))